Suppression of gastric acid with intravenous esomeprazole and omeprazole: Results of 3 studies in healthy subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 45, Issue 6, 2007, Pages 345-354

  Röhss, Kerstin ^a   Wilder Smith, C ^b   Kilhamn, J ^a   Fjellman, M ^a   Lind, T ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b Brain Gut Research Group   (Switzerland)

Author keywords

Acid suppression; Esomeprazole; Healthy subjects; Omeprazole

Indexed keywords

ESOMEPRAZOLE; OMEPRAZOLE; PENTAGASTRIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BOLUS INJECTION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG INDUCED HEADACHE; FEMALE; HELICOBACTER PYLORI; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; MALE; NORMAL HUMAN; OPEN STUDY; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH ACID SECRETION; STOMACH PH; VITAL SIGN;

EID: 34250196881     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP45345     Document Type: Article

References (29)

1. Andersson T, Hassan-Alin M, Hasselgren G, Röhss K, Weidolf L. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet. 2001; 40: 411-426.
2. Andersson T, Röhss K, Bredberg E, Hassan-Alin M. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther. 2001; 15: 1563-1569.
3. Armstrong D. Intravenous proton pump inhibitor therapy: a rationale for use. Rev Gastroenterol Disord. 2005; 5 (Suppl 2): S18-S30.
4. Brunner G, Luna P, Hartmann M, Wurst W. Optimizing the intragastric pH as a supportive therapy in upper GI bleeding. Yale J Biol Med. 1996; 69: 225-231.
5. 2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer. Aliment Pharmacol Ther. 2001; 15: 917-926.
6. Green FW Jr, Kaplan MM, Curtis LE, Levine PH. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology. 1978; 74: 38-43.
7. Julapalli VR, Graham DY. Appropriate use of intravenous proton pump inhibitors in the management of bleeding peptic ulcer. Dig Dis Sci. 2005; 50: 1185-1193.
8. Junghard O, Hassan-Alin M, Hasselgren G. The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH. Eur J Clin Pharmacol. 2002; 58: 453-458.
9. Labenz J, Peitz U, Leusing C, Tillenburg B, Blum AL, Borsch G. Efficacy of primed infusions with high-dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomized controlled study. Gut. 1997; 40: 36-41.
10. Lagerström PO, Persson BA. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. J Chromatogr. 1984; 309: 347-356.
11. Laine L. Endoscopic therapy for bleeding ulcers: room for improvement? Gastrointest Endosc. 2003; 57: 557-560.
12. Laine L, Peterson WL. Bleeding peptic ulcer. N Engl J Med. 1994; 331: 717-727.
13. Larson C, Cavuto NJ, Flockhart DA, Weinberg RB. Bioavailability and efficacy of omeprazole given orally and by nasogastric tube. Dig Dis Sci. 1996; 41: 475-479.
14. Laterre PF, Horsmans Y. Intravenous omeprazole in critically ill patients: a randomized, crossover study comparing 40 with 80 mg plus 8 mg/hour on intragastric pH. Crit Care Med. 2001; 29: 1931-1935.
15. Lau JY, Sung JJ, Lee KK, Yung MY, Wong SK, Wu JC, Chan FK et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med. 2000; 343: 310-316.
16. Lin HJ, Lo WC, Lee FY, Perng CL, Tseng GY. A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy. Arch Intern Med. 1998; 158: 54-58.
17. Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole - a gastric proton pump inhibitor - on pentagastrin-stimulated acid secretion in man. Gut. 1983; 24: 270-276.
18. Merki HS, Wilder-Smith CH. Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing? Gastroenterology. 1994; 106: 60-64.
19. Metz DC, Amer F, Hunt B, Vakily M, Kukulka MJ, Samra N. Lansoprazole regimens that sustain intragastric pH > 6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages. Aliment Pharmacol Ther. 2006; 23: 985-995.
20. Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003; 98: 2616-2620.
21. Netzer P, Gaia C, Sandoz M, Huluk T, Gut A, Halter F, Husler J et al. Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours. Am J GastroenteroL 1999; 94: 351-357.
22. Patchett SE, Enright H, Afdhal N, O'Connell W, O'Donoghue DP. Clot lysis by gastric juice: an in vitro study. Gut. 1989; 30: 1704-1707.
23. Röhss K, Hasselgren G, Hedenström H. Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-h intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci. 2002; 47: 954-958.
24. Röhss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastroesophageal reflux symptoms. Eur J Clin Pharmacol. 2004; 60: 531-539.
25. Schaffalitzky de Muckadell OB, Havelund T, Harling H, Boesby S, Snel P, Vreeburg EM et al. Effect of omeprazole on the outcome of endoscopically treated bleeding peptic ulcers. Randomized double-blind, placebo-controlled multicentre study. Scand J Gastroenterol. 1997; 32: 320-327.
26. van Leerdam ME, Vreeburg EM, Rauws EA, Geraedts AA, Tijssen JG, Reitsma JB, Tyogat GN. Acute upper GI bleeding: did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. Am J Gastroenterol. 2003; 98: 1494-1499.
27. van Rensburg CJ, Hartmann M, Thorpe A, Venter L. Intragastric pH during continuous infusion with pantoprazole in patients with bleeding peptic ulcer. Am J Gastroenterol. 2003; 98: 2635-2641.
28. Wilder-Smith CH, Bondarov P, Lundgren M, Niazi M, Röhss K, Ahlbom H, Nyman L. Intravenous esomeprazole (40 and 20 mg) inhibits gastric acid secretion as effectively as oral esomeprazole: results of two randomized clinical studies. Eur J Gastroenterol Hepatol. 2005; 17: 191-197.
29. Wilder-Smith CH, Röhss K, Bondarov R, Hallerbäck B, Svedberg LE, Ahlbom H. Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study. Aliment Pharmacol Ther. 2004; 20: 1099-1104.